Cancer Research Consortium of West Michigan

COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be greater than or equal to 3 years and less than 22 years at the time of planned enrollment on ACNS1422.

COG ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years. Patients > 12 months and < 21 years of age.

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be < 30 years old at the time of diagnosis.

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
   Patients must be < 50 years of age at enrollment.
2. Standard Risk 1
   Patient must be < 11 years of age at enrollment.
3. Standard Risk 2
   Patients must be ≥ 11 and < 25 years of age at enrollment.

COG-AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell 

Age ≥ 11 years and ≤ 45 years on the date of randomization

COG-AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 year and < 22 years of age at the time of enrollment.

COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone

Age:  > 1 year and < 21 years at ALL diagnosis

COG-AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia - Temporarily closed

Age ≥ 1 year and ≤ 21 years at time of leukemia diagnosis.

COG AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Age - Patients ≥1 year and < 31 years of age at the time of relapse will be eligible.

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. TEMPORARY CLOSURE

COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations - TEMPORARY CLOSURE

Patients must be > 365 days and < 31 years of age

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). All patients must be > 1 and < 31 years of age. TEMPORARY CLOSURE

COG-AHOD1331: A Randomized Phase III Study of Brentuximab vedotin (IND #117117) for Newly Diagnosed Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Ages ≥ 2 - < 22 years at the time of enrollment

COG ANHL12P1: A Randomized Phase 2 study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117. TEMPORARY CLOSURE

Patient must be < 22 years of age.

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
   Patients must be < 50 years of age at enrollment.
2. Standard Risk 1
   Patient must be < 11 years of age at enrollment.
3. Standard Risk 2
   Patients must be ≥ 11 and < 25 years of age at enrollment.

Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

COG ALTE05N1: Umbrella Long-term Follow-up Protocol. Only available to patients already enrolled on a COG intervention protocol.

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

COG ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Age - Patient must be ≥ 365 days and ≤ 30 years of age at diagnosis.

COG-ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) 

Feasibility Phase: Patients must be < 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≤ 40 years of age at the time of enrollment. 

COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma 

Patients ≤ 50 years of age at enrollment will be eligible for this study.